Index

Notes
As the subject of this book is rehabilitation, entries have been kept to a minimum under this heading. Users are advised to seek more specific entries.

Abbreviations
ADHD – attention deficit hyperactivity disorder
CIMT – constraint-induced movement therapy
fMRI – functional magnetic resonance imaging
MRI – magnetic resonance imaging
TBI – traumatic brain injury

A-B-A assessment design, 328, 329
A-B assessment design, 327–328, 329
ability over-estimation, self-efficacy, 237
abnormal development, behavioral self-regulation in children, 494
Aβ protein see beta-amyloid protein (Aβ)
abulia, 213
Academy of Neurologic Communication Disorders and Sciences (ANCDS)
aphasia therapy, 436
cognitive rehabilitation reviews, 108
acceleration-deceleration forces, TBI, 507
accommodation compensation, 26
organic cognitive impairment, 29
N-acetylaspartate (NAA), magnetic resonance spectroscopy, 133
acetylcholine in injury, 308
Parkinson’s disease, 337
TBI, 322
acetylcholinesterase, Alzheimer’s disease, 335
acetylcholinesterase inhibitors, clinical trials
   Alzheimer’s disease, 339–341
dementia with Lewy bodies, 342
acquired focal brain damage, intra-individual variability, 48
activation
   compensation, 28
   neurological recovery, 168
   injury pattern differences, 164
activities of daily living (ADLs)
   activity assessment, 94
   dementia intervention studies, 338, 339
   exercise, negative findings, 259
adaptation, compensation, 27
adaptive behaviors, self-efficacy, 237
“adaptive plasticity”, neurogenesis, 352
addiction, plasticity, 17
adrenalectomy, 65
adrenal steroids, 63–66
   see also catecholaminergic system
adrenergic receptor 1 agonists
   alpha-2-adrenergic mechanisms, 301
   working memory, 301
aerobic activity, 259
   see also exercise/physical activity
aerobic power, 258
affective reversal learning, behavioral/emotional
   self-regulatory function, 466
age-related effects, 149
   brain activity, increased, 152–154
   brain activity, reduced, 150, 151
   brain networks, 154–156, 157
   cerebral microangiopathy, 371
   community-based interventions, 241
coping, 236
   estrogen, memory effects, 67
   intra-individual variability, 47
   locus of control, 236
   memory, 149
   neurogenesis, 357
   neurotrophic factors, exercise/physical activity, 423
   plasticity see neuronal networks
   self-efficacy, 237
aging, 124
   functional imaging, 122
   healthcare costs, 568
   healthy, 417
   MRI subcortical hyperintensities, 132
   psychosocial factors, 233
AIP see Awareness Intervention Program (AIP)
akinetik mutism, 213
   Akt signal transduction see PI3K/Akt signal
   transduction
alertness, TBI effects, 509
   allostasis, 62–78
   alpha-2-adrenergic receptors, 301
   see also noradrenergic function
   alpha-numeric labeling, proximal memory
   aids, 524
   Alzheimer, Aloysius, 128
   Alzheimer’s disease, 125
   Blessed Dementia Scale, 335
   brain networks, 156
   cerebral amyloid angiopathy association, 365, 371
   cerebral hypoperfusion, 262
   compensation, 30
   definition, 251
diet
   docosahexaenoic acid, 278
   excess fat, 277
   high-fat diets, 277
   omega-3 fatty acids, 278
   executive functions, 250, 264
   exercise, 250, 419
   intervention studies see below
   negative findings, 259
   neurotrophic factors, 423
   gait disorders, 265
generation of material-to-be-remembered, 547
   genetics, 335
   insulin signaling, 273, 274, 275
   intra-individual variability, 48
   memory, 541, 542, 543
   “mild cognitive impairment”, 335
   nitric oxide metabolism, 261
   pathology, 334–335
   pharmacological therapy, 296, 312, 322, 339–342
   see also specific drugs
   prevalence, 124, 334
   vascular disease, 260
   Alzheimer’s disease, exercise intervention studies,
   252–256
   Alzheimer’s Disease Assessment Scale (ADAS-cog), 338,
   339, 340
   amantadine
   attention rehabilitation, 510
   energization function rehabilitation, 474
   American Academy of Neurology, 109
   21-aminosteroids, 305
amitriptyline, 211
AMPA receptor(s), 303
AMPA receptor blockers, 304
amphetamines, 308
plasticity in rehabilitation, 15
amplitude, mismatch negativity, 190
amygdala, chronic stress effects, 65
amyloid angiopathy, MRI, 130, 144
anatomic principles, energization functions, 465
androgens, 66, 68
angitis, cerebral amyloid angiopathy, 365
angiogenesis
exercise/physical activity, 418, 420–421
functional imaging, 164
angiopeptin, exercise/physical activity, 420
anhedonia, depression, 298
animal models/studies, 387
cognitive neurorehabilitation, 567
complex environments, 9
exercise/physical activity see exercise/physical activity
focal brain lesion localization, 135
neural stem cell therapy, 376
nitric oxide, 262
plasticity
lesion studies, 12, 13
mPFC lesions, 14
stroke, neural stem cell therapy, 385
ventral hippocampal lesions, plasticity, 17
anisotropic diffusion, diffusion tensor imaging, 134
anoxia, semantic memory, 533
anosognosia, 218–231
anosognosia, treatment, 219–220, 222–223
considerations, 225–226
cost-effectiveness studies, 228
long-term follow-up studies, 228
outcome measures, 220–222, 226–228
anterior cerebral artery aneurysms, 468, 469
anterior cingulate cortex see frontal subcortical circuits; motivation
anterior communicating artery (ACoA), stroke, 468, 470
anterior system for selection and control of responses, attention, 508
anterograde memory, TBI, 321
anticholinesterase (AChE) inhibitors, 296
anticonvulsants, TBI, 323
antidepressants
leptin effects, 69
neurogenesis, 356
antioxidants, 305
clinical trials, 340
antipsychotics, TBI, 324
antisocial behavior, 494
anxiety disorders, 205, 211–212
compensation, 24
corticosteroids, 65–66
apathy, 206, 212–213
Alzheimer’s disease, 264
assessment/treatment, 213
apathy evaluation scale (AES), 474
aphasia, 435–448
anosognosia, 219
aphasia, recovery, 169–172
aphasia therapy, 399, 437
clinical trials, 436
functional impact, 442–444
see also language production therapy; specific therapies
apolipoprotein E gene, Alzheimer’s disease, 335
apomorphine, neglect syndrome rehabilitation, 459
apoptosis
intracellular calcium ions, 304
secondary neurological diseases/disorders, 303
applicability, phase III clinical trial, 86
APP mutation, 366, 367
areal dependency, plasticity see plasticity
Arm Motor Ability Test (AMAT), 406
arousal, anosognosia treatment, 226
arousal, sustained attention and vigilance system, attention, 508
arteriosclerotic microangiopathy, ischemic vascular disease, 363
aspartate, neurotoxicity, 303
assessment(s)
anosognosia neurorehabilitation, 219
tBI pharmacological therapy, 327–328
Assessment of Motor and Process Skills (AMPS), 95
assimilation, compensation, 26
astrocytes, ischemic vascular disease, 362
atheroemboli, ischemic vascular disease, 363
atherosclerosis
functional imaging, 164
nitric oxide, 261
atrophy, Alzheimer’s disease, 335
attention, 299–300
anterior system for selection and control of responses, 508
arousal, sustained attention and vigilance system, 508
assessment, 98
attention (cont.)
definition, 508
focusing, Brief Mindfulness Training, 511
MRI subcortical hyperintensities, 132
neural substrate, 298
pharmacological therapy, 311–312, 313
see also attention, rehabilitation post-TBI
rehabilitation post-TBI see below
resource allocation, 299
sensory selective attentional system, 508
TBI, 321, 508–510
rehabilitation see below
tests
Alzheimer’s disease exercise training, 252
Digit Span test, 508
Digit Symbol Coding test, 508
divided attention tasks, 509
selective attention tasks, 509
Sustain Attention and Response task, 508
Sustained Attention to Response Task, 509, 510
Symbol Digit Modalities test, 508
Trail Making Test, 508
attention, rehabilitation post-TBI, 507–521
attentional control process, dispersion, 50
attention deficit hyperactivity disorder (ADHD), 311, 322, 399, 487–499
attention-demanding actions, neurological recovery, 166
Attention Questionnaire, 98
Attention Rating and Monitoring Scale (ARMS), 98
atypical antipsychotics, TBI, 324
auditory comprehension treatments see language comprehension
auditory cortex, translational research, 84
auditory cueing, 474
auditory discrimination learning
neuroelectric recordings, 182
neuromagnetic recordings, 182
auditory evoked fields (AEFs), 186
auditory evoked potentials (AEPs), 186
auditory evoked responses, somatosensory evoked responses vs., 192
auditory learning
mismatch negativity, 185–190
neural activity measurement, 186–191
auditory tests, attention rehabilitation, 510–512
autobiographical memory, 149
AutoCITE, 408
automation, CIMT, 408
autopsy studies, ischemic vascular disease, 360
aversive consequences, CIMT, 402
avoidance conditioning
neuroelectric recordings, 182
neuromagnetic recordings, 182
avoidance-oriented coping, 235
awareness, compensation see compensation
Awareness Intervention Program (AIP)
deficit awareness, 475
post-TBI anosognosia therapy studies, 224
Awareness Questionnaire, 222
awareness training, anosognosia, 220

Baking Tray Task, 98
Barthel Index
activity assessment, 94
stroke, 94
basal forebrain, vascular dementia, 260
basal ganglia
apathy, 213
cerebral hyperperfusion, 263
cognitive activity assessment, 96
executive functioning, 488
gait, 263
baseline measurements, TBI pharmacologic therapy, 327
BAY x 3702, in injury/repair, 309
BDNF see brain-derived neurotrophic factor (BDNF)
beamformer techniques, neuroelectric recordings, 185
Beck Depression Inventory II, 96
behavioral animal studies, exercise/physical activity see exercise/physical activity
Behavioral Assessment of the Dysexecutive syndrome (BADS)
cognitive activity, 97
effective functions, 99
behavioral contract (BC), CIMT, 411
behavioral disorders
cerebral microangiopathy, 370
cognitive activity assessment, 96
cognitive neurorehabilitation vs., 573
spatial neglect, 172
variability, 5
behavioral/behavioral functions see frontal lobe functions
Behavioral Inattention Test (BIT)
cognitive activity, 97
visual neglect, 98
Behavioral Regulation Index, 495
behavioral score, neurological recovery vs., 164
behavioral self-regulation, in children, 493–495
behavioral therapies
  energization function rehabilitation, 475
  intra-individual variability, 53
neglect syndrome see neglect syndrome rehabilitation
TBI, 399
Behavior Rating Inventory of Executive Function (BRIEF)
in children, post-TBI, 495
everyday activities, 495
TBI vs. ADHD, 496
benzodiazepines, TBI, 324
beta-amyloid protein (Aβ)
  Alzheimer’s disease, 334
cerebral amyloid angiopathy, 364
familial cerebral amyloid angiopathy, 367
insulin signaling, 275
bias
  eligibility criteria, 111
  research evaluation, 106
BICRO39 (Brain Injury Community Rehabilitation Outcome 39), 39, 95
BI-ISG (Brain Injury-Interdisciplinary Special Interest Group), 107
Binswanger’s disease, MRI subcortical hyperintensities, 127, 128
Binswanger’s subcortical leukoencephalopathy (RSLE), 364, 365
biofeedback, ADHD, 499
bipolar affective disorder, 210–211
blinding
  methodological quality evaluation see methodological quality evaluation
  single subject experimental methods see single subject experimental methods
blood supply, lesion-behavior analysis, 141
blood vessel aging, functional imaging, 164
blunt trauma, TBI, 507
body deficits, 91
body functions, 91
body structure
  definition, 87
  outcome measures, 87
BOLD response, functional imaging, 164, 165
bone morphogenic proteins, neurogenesis, 306
Bonferroni correction, lesion-behavior analysis, 141
  “bottom-up” system, attention, 299
boundary conditions
  neuroelectric recordings, 195
  neuromagnetic recordings, 195
BRI2 mutations, 368
brain
  alpha-2-adrenergic receptors, 301
  compensation changes see compensation
damage/injury
  activity measurement, 164
  aging-related changes vs., 152, 156
  awareness/self-regulation, 27
  compensation, 32
  plasticity see plasticity
  see also traumatic brain injury (TBI)
function understanding, 571
imaging techniques, memory impairment
  rehabilitation see memory rehabilitation,
  post-injury
  networks, aging-related changes see age-related effects
  regions, adult neurogenesis, 350
  weight, plasticity models, 9
Brain Age, 417
brain-derived neurotrophic factor (BDNF), 277, 307
compensation, 30
corticosterone effects, 65
enriched housing effects, 382
exercise/physical activity, 422
neural stem cell therapy, 383
neurogenesis, 306, 382, 383
Brain Injury Community Rehabilitation Outcome 39 (BICRO39), 95
Brain Injury-Interdisciplinary Special Interest Group (BI-ISG), 107
Brief Mindfulness Training see attention, rehabilitation
  post-TBI
Broca’s area, aphasia recovery, 171
Brodmann areas
  focal brain lesion localization, 136
  lesion-behavior analysis, 140
bromocriptine
  attention rehabilitation, 510, 512
energization function rehabilitation, 474
  neglect syndrome rehabilitation, 459
  in recovery, 308
  TBI, 324
bromodeoxyuridine assays, adult neurogenesis, 348
Bronx Aging Study, 549
buffer/substitution, compensation, 28
Buschke–Fuld Selective Reminding Test, 338
CA1 pyramidal neurons, 67
androgens, 68
in injury/repair, 310
CA3, chronic stress effects, 64
CA3 cells, loss, 310
CAA see cerebral amyloid angiopathy (CAA)
CADASIL see cerebral autosomal dominant arteriography with subcortical infarcts and leukoencephalopathy (CADASIL)
caffeine, 550
calcium channel blockers, 305
calcium ions, intracellular, 304, 309
calpains
in cell death, 305
intracellular calcium ions, 304
Cambridge Cognitive Examination (CAMCOG), 262
cancellation tasks, neglect syndrome, 450
carbamazepine
bipolar affective disorder, 211
TBI, 324
carbohydrate metabolism, 69
cardiocerebral disease (CVD), 273
caregiver contract (CC), CIMT, 412
CART see codeine and amphetamine regulated transcript (CART)
case-control studies, comprehensive day treatment programs, 240
case study, variability, 52–53
caspases
in cell death, 305
intracellular calcium ions, 304, 305
catecholaminergic system, 307–308
antagonists, 308
augmentation, 308, 313, 314
working memory, 299
categorization, proximal memory aids, 524
Catherine Bergego Scale, 98
“cautious gait”, Alzheimer’s disease, 265
cell damage/death
calpains, 305
caspases, 305
intracellular calcium ions, 304
cellular processes
neurogenesis, 352
plasticity in brain injury, 12
central (cortico-limbic) blindness, anosognosia, 219
central cholinergic tone, injury/repair, 308–309
central GABA tone
effects, 309
injury/repair, 309
central nervous system (CNS), inflammation, 276
central neurotransmitter tone modulation, repair/recovery enhancement, 307–310
central serotonin, in injury/repair, 309–310
cerebellium, intra-individual variability, 49
cerebral amyloid angiopathy (CAA), 362, 364–366, 367, 369
Alzheimer’s disease, 260, 365, 371
familial see familial cerebral amyloid angiopathy (fCAA)
see also ischemic vascular disease (IVD)
cerebral autoregulation, nitric oxide, 261
cerebral autosomal dominant arteriography with subcortical infarcts and leukoencephalopathy (CADASIL), 362, 369
definition, 368–369
cerebral blood flow, exercise see cerebral hypoperfusion; exercise/physical activity
cerebral functions, localization, 6–7
cerebral hypoperfusion
Alzheimer’s disease see Alzheimer’s disease cognition, 262–263
executive dysfunction, 263–264
frontotemporal dementia, 263, 265
gait, 263–264
nitric oxide, 261–262
vascular dementia see vascular dementia (VaD)
vascular disease, 260–261
white matter lesions, 263–264
cerebral microangiopathy, 369–372
cerebral small vessel disease, 360–375
dementia, 128
see also ischemic vascular disease (IVD)
cerebrolysin, 305
cerebrovascular accidents
anosognosia, 219, 220, 222
see also stroke
cerebrovascular disease (CVD), 125
Alzheimer’s disease comorbidity see Alzheimer’s disease diet/nutrition, 273
ischemic vascular disease, 360
MRI subcortical hyperintensities, 132
see also stroke
Charcot–Bouchard aneurysms, 363, 364
chemotaxy, neurogenesis, 353
χ² analysis, 141
choline acetyltransferase (ChAT)
Alzheimer's disease, 335
dementia with Lewy bodies, 337
cholinergic antagonists, 308
cholinergic system
Alzheimer's disease, 335
exercise and nitric oxide, 262
working memory, 299
cholinesterase inhibitors
age-related memory rehabilitation, 550
attention, 312
clinical trials, 343
vascular dementia, 343
Chongqing Aging Study, 549
chronic stress see stress
citalopram, depression, 210
clasmatodendrosis, MRI, 131, 144
classical conditioning, 182
Classification and Regression Tree method (CART), 42
CLASS study, 309
Clinical Dementia Rating scale (CDR), 338
clinical trials, 80–81
cognitive neurorehabilitation, 572
phase I, 4, 6–21
phase II, 4, 6–8
phase III, 4, 6
psychosocial factors, 245
see also randomised clinical trials (RCTs)
Clinician's Global Impression of Change (CGIC), 338
Clinician's Interview Based Impression of Change with caregiver input (CIBIC-plus)
dementia intervention studies, 338, 339
memantine clinical trials, 341
clock-drawing tasks, ADHD, 492
clofazimine, 309
clozapine, bipolar affective disorder, 211
Cochrane reviews
aphasia therapy, 436
community-based interventions, 241
reviews (of cognitive rehabilitation), 108
codeine and amphetamine regulated transcript (CART)
dentate gyrus, 69
plasticity, 68
stress responses, 63
coefficient of variation, 44
cognitive activity assessment, 94, 96–100
cognitive–behavioral therapy (CBT)
attention rehabilitation, 515
compensation, 32
depression, 210
memory impairment rehabilitation, 534, 536
post-TBI anosognosia therapy studies, 224
psychosocial factors, 243
Cognitive Failures Questionnaire (CHQ), 99
cognitive function
aging-related changes, 154
compensation, 24
assessment see above
cerebral hypoperfusion, 262–263
dead, executive functioning vs., 487
corticosteroid effects, 64–65
delay
compensation, 25
MRI subcortical hyperintensities, 132
defects see below
dietary antioxidants, 280
enriched housing, 381
neurogenesis see neurogenesis
optimism vs., 238, 239
performance vs., 573
self-efficacy vs., 238
variability, 50
cognitive function defects
apathy, 213
causes, 311
cerebrovascular disease, 125
insulin resistance, 276
metabolic syndrome, 276
neglect syndrome, 450
stroke, 377
TBI, 507
comorbidities, 311
as economic burden, 568
insulin, 69
signaling, 274
pharmacological therapy see pharmacological therapy
prevalence, 568
therapy see cognitive neurorehabilitation
Cognitive Log (Cog-Log) scale, 99
cognitive neurorehabilitation, 569
assessment, 566–568
attentional demands, 567
costs, 571
definition, 565
cognitive neurorehabilitation (cont.)
efficacy, demonstrability, 570
everyday tasks, 570
evidence-based therapy, 570
examples, 570–573
future work, 565–574
investment in, 568
models, 570
multilevel integration, 566–567
protocol necessity, 570
psychosocial factors, 243
as science, 568–570
amelioration of symptoms, 572
brain function understanding, 571
clinical trials, 572
everyday life function, 572
imaging importance, 572
structure, planned, 571
testing, 572

cognitive-phenomenological theories, psychosocial factors
theories/models, 233
cognitive psychological models, post-TBI anosognosia
therapy studies, 223
cognitive system recruitment, word level treatments, 438
cognitive tests, outcome measures, 92
collaterals, compensation, 29
combination therapies
cognitive neurorehabilitation, 574
TBI, 323, 324
commercial services, paging systems, 531
communication difficulties, mood assessment, 96
Communicative Activities of Daily Living, 99
community-based autopsy studies, Alzheimer’s disease-
cerebrovascular disease comorbidity, 126
community-based interventions see psychosocial factors
community-based investigations, ischemic vascular
disease, 360
Community Integration Measure, 100
compensation, 4, 22–38
aging-related changes, 154
competitive spatial bias, neglect syndrome, 451
complex environments, animal models see animal
models/studies
complexity, treatment descriptions, 113
compliance, treatment descriptions, 114
comprehensive day treatment programs (CDTPs) see
psychosocial factors
computational methods, MRI subcortical
hyperintensities, 132
computational lesion analysis, 137
computerised tomography (CT)
introduction, 128
right hemisphere hypodensity, 137
computerised training
attention rehabilitation, 510, 511
auditory comprehension treatments, 442
neglect syndrome rehabilitation, 455
selective attention rehabilitation, 512
concentration, TBI, 322
conditioned responses, CIMT, 403
confrontation naming, word level treatments, 437
connectivity, normal aging, 150
constraint induced language therapy (CILT), 443
constraint-induced movement therapy (CIMT), 397, 401,
443, 570
adherence-enhancing behavioral methods, 410–412
application of, 405–407
stroke, 377
behavioral contract, 411
caregiver contract, 412
constraining use of more-impaired upper extremity, 410
protective safety mitt, 410
daily schedule, 412
definition, 401
efficacy, 401
historical aspects, 405
home diary, 411
home practice, 412
home skill assignment, 411–412
importance, 570
overcoming learned non-use, 402–404
protocols, 407–412
see-also individual protocols
as rehabilitation model, 571
repetitive task-oriented training, 407–410
studies, 405
theoretical basis, 402–404
therapeutic factors, 412–413
use-dependent cortical reorganization, 404–405
without physical restraint, 410
contextual therapy, psychosocial factors, 245
continuous behavior, lesion-behavior analysis, 141
continuous memory recovery, 42
Continuous Performance Tasks, 512
continuous scales, impairment measures, 93
contralateral pattern, neurological recovery, 168
Controlled Oral Word Association Test, 512
coping see psychosocial factors
coping skills group, 242

copying objects, neglect syndrome, 450

cortex

aging-related changes

functional imaging, 156

visual areas, 152

neural stem cell therapy, 386

plasticity, compensation, 29

remodeling

event-related fields, 184

event-related potentials, 184

cortical maps, 193

corticobasal degeneration (CBD), 336

corticosteroid(s)

anxiety effects, 65–66

chronic stress, 64

cognitive function effects, 64–65

dendritic retraction, 64

memory effects, 65–66

neural structure effects, 64–65

neurogenesis, 65

receptors, 64

corticosteroid receptors, glial cells, 65

corticosterone, 65

corticostriatal dysfunction, ADHD, 497

cortisol, neurological effects, 64

cost-effectiveness

anosognosia neurorehabilitation, 228

neurocognitive rehabilitation, 571

Craig Handicap Assessment and Reporting Technique, 100

cross-sectional studies

exercise/physical activity see exercise/physical activity

neurological recovery, 169

cued-recall tasks, compensation, 30

Cueing Verbs Treatment (CVT), 439

cues, word level treatments

creation, 437

hierarchies, 437

current, apical dendrites, 184

Cushing’s disease, 66

hippocampal atrophy, 64

steroid therapy, 70

cystatin C mutations, 368

cystic encephalomalacia, 362

cystic infarcts, 362

daily schedule (DS), CIMT, 412

“Darwinian concept of stress”, 63

data, scatter, 46

data storage/analysis

neuroelectric recordings, 185

neuromagnetic recordings, 185

single subject experimental methods, 329

“day-to-day” variability, 43

decision making/motivation, children, 492–493

declarative memory therapy, 313

deep white subcortical hyperintensities, MRI, 129, 143

deficit awareness see metacognitive function rehabilitation definition, three-dimensional MRI, 138

delirium, pharmacological therapy, 302

delivery and impact see Rothi’s revision of the Robey model
dementia, 125–126

apathy, 213

exercise see below

pathology, 334–337

pharmacological therapy see below

see also specific diseases/disorders
dementia, exercise intervention studies, 256–258
dementia, pharmacologic therapy, 296, 334–347
dementia with Lewy bodies

compensation, 30

intra-individual variability, 48

Parkinsonism, 337

Parkinson’s disease, 337

pathology, 336–337

pharmacologic clinical trials, 342–343
dendritic length, plasticity, 11

dendritic morphology

age-related plasticity, 13

plasticity, 7

dendritic retraction, corticosteroids, 64

dendritic spines, estrogen receptors, 66

denial of disability (DD), anosognosia treatment, 225

density plots, lesion-behavior analysis, 141, 142
dentate gyrus

androgens, 68

codeine and amphetamine regulated transcript, 69

neurogenesis, 65, 379

Department of Veterans Affairs Taskforce on Aphasia, 436

L-deprenyl, 308

depression, 206–209

apathy see apathy

assessment, 208–210

cognition vs., 351

intra-individual variability, 49
depression (cont.)
pseudodementia, 209–210
treatment, 210
memory impairment rehabilitation, 534, 536
pharmacotherapy, 207
design features, distal memory aids, 525
determinants
anosognosia therapy outcome, 219
psychosocial factors, 239
device-requiring therapies see neglect syndrome rehabilitation
DEX see Dysexecutive Questionnaire (DEX)
dexamethasone suppression test, 209
dextromethorphan, pseudobulbar affect treatment, 211
DHA see-docosahexaenoic acid (DHA)
DHEA, 68
DHT, 68
diabetes mellitus, type-2 see type-2 diabetes mellitus
diaschisis
functional imaging, 165
injury, 162
lesion-behavior analysis, 141
diazepam, in stroke, 309
dietary antioxidants, 272, 279–280
diet/nutrition, 272–291
dietary restriction, 204
neurogenesis, 70
insulin resistance see insulin resistance (IR)
see also specific nutrients
diffuse axonal injury (DAI), TBI, 303, 321, 469
diffusion tensor imaging (DTI), 134
ADHD, 497
fractional anisotropy, 131, 134
MRI, 132
sensitivity, 133
structure, 133
Digit Span test, 508
Digit Symbol Coding test, 508
Digit Symbol measures, 327
direct cortical electrical stimulation, plasticity, 16
directional motor defects, neglect syndrome, 451
disability, outcome measures, 87
disconnection syndrome, lesion-behavior analysis, 141
discourse level training, verbal fluency, 440
discovery phase, Rothi’s revision of the Robey model, 82
discrepancies, reviews (of cognitive rehabilitation), 108
discriminating training, neural activity measurement, 188
disengaging attention, neglect syndrome, 451
dispersion
intra-individual variability, 43
variability see variability
dispositional optimism, 238, 239
distal memory aids see memory rehabilitation, post-injury
distractibility, TBI, 322
distraction reduction, attention rehabilitation, 516
distributed practice, memory impairment rehabilitation, 527
diurnal rhythms, intra-individual variability, 47
divided attention, 514
TBI effects, 509
docosahexaenoic acid (DHA)
Alzheimer’s disease, 278
in brain, 278
dietary supplementation effects, 279
gene expression effects, 279
PI3K/Akt signaling, 279
domain-specific expertise, elderly memory rehabilitation, 553
domain-specific functions, variability, 50
donepezil
attention, 312
clinical trials
Alzheimer’s disease, 339–340, 341
vascular dementia, 343
declarative memory, 313
executive functions, 313
memory, 313
TBI, 324
dopamine, 300
TBI, 322
dopamine agonists
apathy, 212, 213
in recovery, 308
dopamine D1 receptor agonists
neglect syndrome rehabilitation, 459
spatial working memory, 300
dopamine D1 receptor antagonists, 300
dopamine D2 receptor agonists, 459
dopaminergic drugs
apathy, 206
neglect syndrome rehabilitation, 459
dopaminergic system, executive functions, 300
dorsolateral prefrontal (DLPF) see frontal subcortical circuits
dorsolateral stroke syndrome, 468
double-blind trials, methodological quality
evaluation, 112
double dissociation of symptoms, neurological recovery, 175
drive, definition, 204

drugs
anxiety disorders, 212
development targets, Alzheimer’s disease, 335
induced behavioral sensitization, 8
induced morphological changes, 10
DTI see diffusion tensor imaging (DTI)
dual coding, mnemonics, 528
dual task performance, executive/cognitive function rehabilitation, 472
Dysexecutive Questionnaire (DEX) attention assessment, 98
executive functions assessment, 99
dyslexia, event-related potentials, 193

EAAs see excitatory amino acids (EAAs)
early GABA-ergic activation study in stroke (EGASIS), 309
ECG (electrocardiography), Alzheimer’s disease exercise training, 252
ecological validity

cognitive activity assessment see cognitive activity assessment
outcome measures, 115
ECT (electroconvulsive therapy), depression, 210
Edinburgh Functional Communication Profile, 99
education effects
intra-individual variability, 47
normal aging, 156, 157
EEG see electroencephalography (EEG)
efficacy (of therapy), 121
evaluation, cognitive neurorehabilitation, 569
phase II clinical trial, 85
phase III clinical trial, 86
rehabilitation research phase models, 82
EGASIS (early GABA-ergic activation study in stroke), 309
EGF see epidermal growth factor (EGF)
elderly see age-related effects
electrical brain stimulation, plasticity, 12, 16
electrocardiography (ECG), Alzheimer’s disease exercise training, 252
electroconvulsive therapy (ECT), depression, 210
electroencephalography (EEG), 182, 183, 185–190
ADHD, 499
exercise/physical activity, 427
electrolytes, homeostasis, 62
electrophysiological studies, TBI effects, 509
elevators, distal memory aids, 525
eligibility criteria, methodological quality evaluation see methodological quality evaluation
(S)-emopamil, 305
emotional aspects
apathy, 212
memory impairment, 534–535
rehabilitation see memory rehabilitation, post-injury
post-TBI anosognosia therapy studies, 224
emotional self-regulation training, 472
emotion-focused coping, 235
employment status, anosognosia therapy, 222
encoding strategies, age-related memory rehabilitation, 545
encoding self-initiation, 542
endogenous stem cells, neural stem cell therapy, 378
endothelial nitric oxide synthase (eNOS), 261
energization function
rehabilitation see frontal lobe functions, rehabilitation see frontal lobe functions
energy balance
homeostasis see homeostasis
sedentary lifestyle, 70
enriched housing
brain derived neurotrophic factor, 382
cognitive functions, 351, 381
fibroblast growth factor, 382
nerve growth factor, 382
neurogenesis, 379, 381
environment
attention rehabilitation see attention, rehabilitation post-TBI
cognitive function enhancement, 311
memory rehabilitation, elderly, 545, 554
neurogenesis see neurogenesis
TBI in children, 489
epidemiological studies, exercise/physical activity see exercise/physical activity
epidermal growth factor (EGF)
nervous system, 382, 383, 386
neurogenesis, 306
epinephrine, TBI, 307
episodic memory, 299
aging-related changes, 149, 152, 542, 543
Alzheimer’s disease, 542, 543
compensation, 31
focal brain lesion localization, 135
ERFs see event-related fields (ERFs)
ERPs see event-related potentials (ERPs)
error awareness/self-monitoring see metacognitive function rehabilitation
errorless learning
age-related memory rehabilitation, 552–553
Alzheimer’s disease, 553
memory impairment rehabilitation see memory rehabilitation, post-injury
semantic memory rehabilitation, 533
erythropoietin, neural stem cell therapy, 382, 383, 386
stroke, 385
estrogen(s), 66–68
estrogen receptors (ERs), 66
estrus cycle, 66
état crible, MRI, 143
ethics
anosognosia neurorehabilitation, 220
single subject experimental methods, 328
European Federation of Neurological Societies, 107
event-related fields (ERFs), 192–194
cortical remodeling, 184
definition, 184
mismatch negativity, 190
event-related potentials (ERPs), 122, 192–194
cortical remodeling, 184
definition, 184
exercise/physical activity, 427
mismatch negativity, 190
rapid time periods, 122
everyday activities
cognitive neurorehabilitation, 570, 572
TBI vs. ADHD, 496
Everyday Memory Questionnaire, 97
evidence-based research/therapy, 81, 106–108
cognitive neurorehabilitation, 570
see also reviews (of cognitive rehabilitation)
excision, plasticity, 12
excitatory amino acids (EAs), 303–304
exclusion criteria, 112
executive dysfunction, 264, 398
ADHD, 487
TBI vs., 496
Alzheimer’s disease see Alzheimer’s disease
cerebral hypoperfusion, 263–264
frontotemporal dementia, 250, 264–265
frontotemporal lobar degenerations, 336
pseudodementia, 209
TBI, 321, 487, 488
ADHD vs., 496
vascular dementia, 250, 264
executive dysfunction, rehabilitation, 478, 471–472
pharmacological therapy, 313
assessment, 99
developmental perspective, 488
see also neural substrate below
dysfunction see executive dysfunction
exercise/physical activity, 250
longitudinal studies, 428
neural substrate, 298, 488–489
tests
coping, 235
reaction time tasks, 466
see also specific executive functions
executive functions, children, 489–495
Executive Plus, psychosocial factors, 245
exercise/physical activity, 204, 250–271, 281, 397, 417–434
age-related memory rehabilitation, 549–550
angiogenesis see angiogenesis
cerebral blood flow, 245, 259
cognition, 351
fMRI, 427
intensity effects, 245
negative findings, 245
Activity of Daily Living, 259
aerobic activity changes, 259
Alzheimer’s disease, 259
Instrumental Activity of Daily Living, 259
subcortical ischemic vascular dementia, 259
neurogenesis, 70, 379, 418, 421–422
observational studies, 423–426
ex-Gaussian distributions see variability
existing function optimization, age-related memory rehabilitation see memory rehabilitation, elderly
exogenous stimulation see neural stem cell therapy
Expanded Disability Status Scale, 93
expanded rehearsal, memory impairment, 526, 529
experience, age-related memory, 549
experience dependent plasticity, Rothi’s revision of the Robey model, 84
explanatory optimism, 238
explicit memory rehabilitation, 552
explicit recall, errorless learning, 529
Exploratory Clinical Study see Rothi’s revision of the Robey model
Extended Activities of Daily Living (EADL), 94
external compensation, age-related memory rehabilitation, 554
external cueing, behavioral/emotional function rehabilitation, 474
external locus of control, psychosocial factors, 236
external memory aids see memory rehabilitation, elderly extrapersonal neglect, neglect syndrome, 449
eye patching, neglect syndrome rehabilitation, 458
false negatives, functional imaging, 165
familial cerebral amyloid angiopathy (CAA), 366–368
familial noncerebral amyloid angiopathy cerebral microangiopathies, 362
familial syndromes of cerebral microangiopathy, 368–369 see also specific diseases/disorders
family anxiety, memory impairment rehabilitation, 535
family history, depression, 208
family input, memory impairment rehabilitation, 535
fatigue, depression, 208
feature integration reaction time tasks, dispersion, 51
feedback training, neglect syndrome rehabilitation, 452
FGF see fibroblast growth factor (FGF)
FGF-2 see fibroblast growth factor-2 (FGF-2)
neurogenesis, 306
regeneration, 14
FIM see Functional Independence Measure (FIM)
fitness measures, epidemiological studies, 425
5HT see serotonin
FLAIR see fluid attenuated inversion recovery (FLAIR)
fluid attenuated inversion recovery (FLAIR)
cerebral microangiopathy, 369
MRI, 126, 138
fluvoxamine, clinical trials, 342
focal brain lesion localization see imaging
cerebral microangiopathies, 369
MRI, 126, 138
fluvoxamine, clinical trials, 342
cognitive activity assessment, 96
inter-individual variability, 42
intra-individual variability, 43–46, 52
disorders, 398, 468–470
see also specific diseases/disorders
functions see below
intra-individual variability, 49
lesions, dispersion, 51
normal aging, 151
functional imaging, 150, 156
subcortical circuits see frontal subcortical circuits variability, 50
frontal lobe functions, rehabilitation, 470–478
frontal subcortical circuits, 205–206
fronto-cortical circuits, white matter lesions, 263
fronto-hippocampal circuits, white matter lesions, 263
frontoparietal cortex, exercise/physical activity, 420
fronto-striatal system, white matter lesions, 263
frontotemporal dementia (FTD)
cerebral hypoperfusion, 263, 265
definition, 251
executive dysfunction, 264–265
executive functions, 250
exercise intervention studies, 256
gait disorders, 265, 266
vascular disease, 261
frontotemporal lobar degenerations (FTLDs), 336
pharmacologic therapy, 342
symptoms, 336
see also specific diseases/disorders
frontotemporal Mild Cognitive Impairment (FT-MCI), 266
fructose administration, 282
FTD see frontotemporal dementia (FTD)
FTLDs see frontotemporal lobar degenerations (FTLDs)
Functional Assessment Measure (FAM), 95
Functional Assessment of MS, 95
Functional Assessment Staging scale (FAST), 341
Functional Communication Profile, 99
functional conversation skills, 440
functional imaging, 121, 162–181, 566
applications, 122
ADHD, 489
effective functioning, 488
frontal lobe function rehabilitation, 478
Huntington’s disease, 208
depression see depression
intra-individual variability, 49
functional imaging (cont.)
normal aging, 122, 149–161
Parkinson’s disease, 207, 208
short-term changes, 149
see also specific methods
Functional Independence Measure (FIM)
activity assessment, 94
deficit awareness, 475
multiple sclerosis assessment, 95
functional integration, adult neurogenesis, 348
functional interactions, injury, 164
functional localization, neurological recovery, 175
functional magnetic resonance imaging (fMRI), 122
ADHD, 489
anosognosia treatment outcome measures, 226
aphasia recovery, 169
GMRT, 404, 405
compensation, 32, 33
depression assessment, 210
exercise/physical activity, 427
lesion-behavior analysis, 140
neurological recovery, 175
Patient Competency Rating Scale, 227
stroke, 122
TBI effects, 509
funding
randomized clinical trials, 81
rehabilitation research, 79
GABA, distribution, 309
GABA-ergic neurons, adult neurogenesis, 350
GABAergic system, executive functions, 300
gait, cerebral hypoperfusion see cerebral hypoperfusion
gait disorders, 265–266
MRI subcortical hyperintensities, 132
galantamine
attention, 312
clinical trials
Alzheimer’s disease, 340–341
vascular dementia, 343
gene expression effects, docosahexaenoic acid, 279
General Health Questionnaire
general psychological distress, 96
mood assessment, 96
generalization
aphasia therapy, 442
mnemonics, 528
generalized synaptic loss, frontotemporal lobar
degenerations, 336
genetic–environment interactions, lesion-behavior
analysis, 141
Genetic Evaluation by Relative’s Rating Instrument
(GERRI), 343
genetics
neurogenesis models, 354
plasticity studies, 12
ghrelin receptors, 68, 69
ginkgo biloba, vascular dementia clinical trials, 343
Glasgow Coma Scale, event-related potentials vs., 193
glial cell(s)
adult neurogenesis, 348
corticosteroid receptors, 65
neural stem cell transplantation, 384
glial cell line-derived neurotrophic factors, 306, 307
glioblastomas, 469
gliomas, 469
globus pallidus, frontal subcortical circuits, 206
glucocorticoid(s), 63, 64
glucocorticoid receptor (GR), 64
expression reduction, 66
spatial learning, 66
glucose
administration effects, 282, 283
age-related memory rehabilitation, 550
depletion effects, 282
GLUT4 receptor, 69
glutamate
Alzheimer’s disease, 335
neurotoxicity, 303
restraint stress, 64
glutamatergic system, estrogen receptors, 66
glutamatergic system, executive functions, 300
Goal Management Training (GMT)
atention rehabilitation see attention, rehabilitation
post-TBI
behavioral/emotional function rehabilitation, 473
“goal neglect”, behavioral/emotional function
rehabilitation, 472
goals, age-related memory rehabilitation, 544
gonadal steroids, 66–68
go/no-go performance, in children, post-TBI, 491
Gordon Diagnostic System (GDS), attention
rehabilitation, 512
GRADE working group, 109
gradient echo imaging, MRI, 133
grammatic impairment, phrase/sentence level treatment, 439
“granular atrophy”, ischemic vascular disease, 362
group effects, variability, 39
group therapy, psychosocial factors, 243

group variability, scatter see scatter

guanfacine, neglect syndrome rehabilitation, 460

Guttman scaling, activity assessment, 94

Guys Neurological Disability Scale, 93

Hair Combing Task, 98

Halstead–Reitan Battery, 471

Harmonization Consensus guidelines, MRI, 133

head/trunk rotation, neglect syndrome rehabilitation, 455

healthcare costs, aging, 568

heart rate change, exercise, 259

Helm Elicited Program for Syntax Stimulation (HELPSS), 439

hemianopias, anosognosia, 219

hemiblinding, neglect syndrome rehabilitation, 458

hemiplegia, anosognosia, 218

hemorrhagic stroke, 376

HERNS, 362

definition, 369

herpes encephalitis, 476

“hidden costs”, compensation, 28

higher cognitive functions

compensation, 28

coping, 235

high glycemic index foods, 283

high-involvement goal setting, behavioral/emotional function rehabilitation, 473

high quality fats, chronic diet, 272

hippocampal sclerosis (HS), 364

hippocampus

adult neurogenesis, 348

aging-related changes, 152

connections, 155

atrophy

glucocorticoids, 64

major depression, 64

post-traumatic stress disorder, 64

cerebral hyperperfusion, gait, 263

cognition, 351

Cushing’s disease, 64

focal brain lesion localization, 134

gonadal steroids, 67

insulin signaling, 274

memory, aging effects, 543

neurogenesis

exercise/physical activity, 421

training, 354

plasticity, 10

TBI, 321

hippocampus dentate gyrus, neurogenesis, 352

history taking

apathy, 213

depression see depression

HIV infection, pseudodementia, 209

holistic methods

anosognosia treatment, 223, 226

memory impairment

rehabilitation, 534

homeostasis

definition, 62

electrolytes, 62

energy balance, 62

peptide hormone receptors, 68

mediators, 62

home practice (HP), constraint-induced movement therapy, 412

home skill assignment (HSA), constraint-induced movement therapy, 411–412

homocysteine

exercise and nitric oxide, 262

vascular dementia, 262

vascular disease, 261

hormones, 62–78

Hospital Anxiety and Depression Scale, 96

“house-keeping” operations, neurological recovery from injury, 162

Huntington’s disease

animal models/studies, 384

fibroblast growth factor-2, 383

anxiety disorders, 211

depression, 208

functional imaging, 208

neurotrophic factors, exercise/physical activity, 423

positron emission tomography, 208

stem cell therapy, 307

6-hydroxypaminorex, Parkinson’s disease, 419

hypercortisolemia, 64

hyperpolarization-activated cyclic nucleotide-gated cation channels, 301

hypertension

chronic diet, 273

microvascular disease, 363

MRI subcortical hyperintensities, 132

hyperthyroidism, apathy, 213

hypoparathyroidism, apathy, 213

hyperperfusion, cerebral see cerebral hypoperfusion

hypothalamic-pituitary-gonadal (HPG) axis, 66
hypothalamus, adult neurogenesis, 350
hypoxia-inducible factor (HIF), exercise/physical activity, 420
IADL scale, deficit awareness, 475
idiopathic Parkinson’s disease, 337
imaging, 3, 566
compensation, 28, 30–31
depression, 207
focal brain lesion localization, 134–141
functional see functional imaging
image acquisition, 137–138
lesion-behavior analysis, 140–141
plasticity, 182
rapid time periods, 122
spatial normalization, 138–139
stroke, 122
structural see structural imaging
volume information, 138
see also specific methods
immediate damage, secondary neurological diseases/disorders, 303
immunohistochemistry, ischemic vascular disease, 362
impaired self-awareness (ISA) see anosognosia
implicit learning, errorless learning, 528, 529
implicit memory, age-related memory rehabilitation, 551–553
in-built alarms, memory impairment rehabilitation, 526
inclusion criteria, 112
Rothi’s revision of the Robey model, 85
inconsistency see variability
inflammation
central nervous system, 276
cerebral amyloid angiopathy, 365, 367
insulin resistance, 276–277
neurogenesis, 353
neurological diseases/disorders, 298
secondary neurological diseases/disorders, 303
type-2 diabetes mellitus, 276–277
information sharing, cognitive neurorehabilitation, 573
integration, cognitive neurorehabilitation, 566
intrinsic encoding see memory rehabilitation, elderly
integrity, treatment descriptions, 114
intelligence effects, intra-individual variability, 47
intentional systems, word level treatments, 438
intent-to-treat analysis, methodological quality evaluation, 115
interactive modeling training, executive/cognitive function rehabilitation, 471
interhemispheric imbalance correction, neglect syndrome see neglect syndrome rehabilitation
inter-individual variability, 41–43
internal locus of control, 236
internal validity, indicators, 110
International Classification of Functioning, Disability and Health (ICF), 87–88, 91
international clinical trials network, cognitive neurorehabilitation, 573
inter-rater reliability, definition, 92
intervention studies, exercise see exercise/physical activity
intracortical microstimulation studies, CIMT, 404
levels of organization, 162, 163
neurotransmitter receptors, 162
see also traumatic brain injury (TBI)
"inner speech", 474
innovation stage
Rothi’s multistage model, 4
Rothi’s revision of the Robey model, 85
Institutional Review Boards, 328
Instrumental Activity of Daily Living, 259
insulin, 68, 69
insulin, signaling, 272, 273–278
insulin-like growth factor-1 (IGF-1), 277, 307
exercise/physical activity, 420
neural stem cell therapy, 382, 383
neurogenesis, 69
exercise/physical activity, 421
insulin receptors, 68, 69
insulin resistance (IR), 276
chronic diet, 273
dietary effects, 277–278
insulin signaling, 276–277
lifestyle effects, 277
neurotrophins, 277
oxidative stress, 276–277
intact function substitution see memory rehabilitation, elderly
integration, cognitive neurorehabilitation, 566
integrative encoding see memory rehabilitation, elderly
integration, treatment descriptions, 114
intelligence effects, intra-individual variability, 47
intentional systems, word level treatments, 438
intent-to-treat analysis, methodological quality evaluation, 115
interactive modeling training, executive/cognitive function rehabilitation, 471
interhemispheric imbalance correction, neglect syndrome see neglect syndrome rehabilitation
inter-individual variability, 41–43
internal locus of control, 236
internal validity, indicators, 110
International Classification of Functioning, Disability and Health (ICF), 87–88, 91
international clinical trials network, cognitive neurorehabilitation, 573
inter-rater reliability, definition, 92
intervention studies, exercise see exercise/physical activity
intracortical microstimulation studies, CIMT, 404
intra-individual variability, 43–46, 52
acquired focal brain damage, 48
affecting factors, 46–49
Alzheimer’s disease, 48
Attention Deficit Hyperactivity Disorder, 48
depression, 49
functional imaging, 49
Lewy body disease, 48
malingering, 39–41, 54
neurological disorders, 46, 48–49
see also specific diseases/disorders
neuropsychiatric disorders, 49
see also specific diseases/disorders
Parkinson’s disease, 48, 49
task factors, 47
population factors, 46, 47–48
progressive forms, 48
rehabilitation therapy, 53–54
schizophrenia, 49
situational factors, 46, 47
task factors, 46, 47
TBI, 48, 49
time scales, 43
vascular dementia, 48
intra-rater reliability, definition, 92
Iowa Gambling Task, 493
IQ level effects, coping, 236
irrelevant information, aging-related changes, 152
ischemic stroke, 376
ischemic vascular disease (IVD), 297, 360
astrocytes, 362
autopsy studies, 360
community-based investigations, 360
epidemiology, 361
"granular atrophy", 362
lesions, 361, 362
microglia, 362
neuropathologic substrates/correlates, 361, 362–364
isotropic diffusion, diffusion tensor imaging, 134
IVD see ischemic vascular disease (IVD)
kainate receptors, excitatory amino acids, 303
Kl–67 expression, neurogenesis, 356
Korsakoff’s syndrome, apathy, 213
labeling, proximal memory aids, 524
laboratory motor tests, CIMT efficacy, 406
lactate, magnetic resonance spectroscopy, 133
lacunar infarcts, ischemic vascular disease, 362, 363
lacunes, MRI, 127, 143
language assessment, 99
cerebral location, 7
classification/subdivisions, 436
comprehension see below
disorders, phase II clinical trial, 86
learning, example of, 84
production therapy see below
reorganization, event-related potentials, 193
see also aphasia
language comprehension, 441–442
language production therapy, 437–438, 572
phrase/sentence level treatment, 438–439
word level treatments, 437–438, 443
see also aphasia therapy
language system rehabilitation, 398
lapse minimization, proximal memory aids, 525
Last Observation Carried Forward (LOCF) analysis clinical trials, Alzheimer’s disease, 341
memantine clinical trials, 341
latent skill substitution, compensation, 26
lateral orbital cortex, frontal subcortical circuits, 206
lateral prefrontal cortex (LPFC)
aging-related changes, 155
executive cognitive functions, 465
lateral temporal cortex, memory, aging effects, 544
lazeroids, 305
LCFS (Level of Cognitive Functioning Scale), 99
learning
neurogenesis, 354, 356, 379
omega-3 fatty acids, 279
left hemiplegia, anosognosia therapy outcome, 221
left prefrontal cortex, memory, aging effects, 543
left sided vestibular stimulation, neglect syndrome rehabilitation, 456
left superior temporal gyrus, aphasia recovery, 165
left temporal cortex, aphasia recovery, 171
legislation, Rothi’s revision of the Robey model, 86
leisure activities, age-related memory rehabilitation, 549–550
leptin, 68
antidepressant effects, 69
stress responses, 63
leptin receptors, 68, 69
lesion(s)
anterior cingulate cortex, 206
behavior analysis, imaging see imaging
lesion(s) (cont.)
dorsolateral prefrontal, 206
frontal subcortical circuits, 206
ischemic vascular disease see ischemic vascular disease (IVD)
location, inter-individual variability, 42
masking, imaging spatial normalization, 138, 139
orbitofrontal circuit, 206
studies
animal models of plasticity, 12, 13
dispersion, 51
subtraction analysis, 140
letter fluency tasks, executive/cognitive function rehabilitation, 472
leukocaraitasis
ischemic vascular disease, 360, 362
MRI subcortical hyperintensities, 127, 130
leukoencephalopathy, MRI subcortical hyperintensities, 127
Level of Cognitive Functioning Scale (LCFS), 99
levodopa
neglect syndrome rehabilitation, 459
pseudobulbar affect treatment, 211
levodopa-carbidopa, attention therapy, 510, 512
Lewy bodies
definition, 337
see also dementia with Lewy bodies
life history stage
allostasis, 63
diseases/disorders, 63
lifestyle
exercise/physical activity, epidemiological studies, 424
insulin resistance, 277
lifetime psychiatric disorders, TBI vs. ADHD, 495
limb activation therapy, neglect syndrome rehabilitation, 453
linear transformation, imaging spatial normalization, 139
line bisection, neglect syndrome, 450
Linguistic Specific Treatment (LST), 439, 442
lipohyalinosis, ischemic vascular disease, 363
listening exercise example, Rothi’s revision of the Robey model, 84
lithium, bipolar affective disorder, 211
living conditions, adult neurogenesis, 349
living situation effects, optimism, 239
LLL example
phase II clinical trial, 86
Rothi’s revision of the Robey model, 84, 85
location detection devices, memory impairment rehabilitation, 530–531

LOCF see Last Observation Carried Forward (LOCF) analysis
locus ceruleus (LC), alpha-2-adrenergic receptors, 301
locus of control see psychosocial factors
London Handicap Scale, 100
longitudinal studies
exercise/physical activity see exercise/physical activity
fMRI study,aphasia recovery, 170
neuroelectric recordings, 194
neurological recovery, 169
neuromagnetic recordings, 194
optimism, 238
long-term follow-up studies, anosognosia therapy, 228
long-term potentiation
brain-derived neurotrophic factor, 277
exercise/physical activity
neurogenesis, 421
neurotrophic factors, 422
insulin signaling, 275
low glycemic index foods, 283
LPFC, see lateral prefrontal cortex (LPFC)
LST (Linguistic Specific Treatment), 439
Luria’s verbal self-regulation, case study, 53
magnesium ion blockade, excitatory amino acids, 303
magnetic resonance imaging (MRI), 126, 163
amyloid angiopathy, 130, 144
cerebral microangiopathy see cerebral microangiopathy
classmatodendrosis, 131, 144
depression, 207, 210
diffusion tensor imaging, 132
exercise/physical activity, 429
fluid attenuated inversion recovery, 126, 138
functional see functional magnetic resonance imaging (fMRI)
gradient echo imaging, 133
intensity differences, 126
introduction, 128
magnetization transfer imaging, 133
multiple sclerosis, 130, 144, 207
pathological changes, 126
proton density, 126
signal abnormalities, 143–144
standardized acquisition, 133
structural see structural magnetic resonance imaging
subcortical hyperintensities see below
T1-weighted imaging, T2 vs., 138
T2-weighted imaging, 133
quantitative, 132
T1 vs., 138
three-dimensional, 135, 138
two-dimensional, 135
volumetric analysis
executive functioning, 488
TBI, 497
magnetic resonance imaging (MRI), subcortical
hyperintensities, 126
aging, 132
attention disorders, 132
cerebrovascular disease, 132
clinical relevance, 132
cognitive decline, 132
gait disorders, 132
historical overview, 127–131
hyperintension, 132
mental processing speed, 132
motor dexterity, 132
quantification, 131–133
magnetic resonance spectroscopy, 132, 133
magnetization transfer (MT) imaging see magnetic
resonance imaging (MRI)
magnetization transfer ratio, 132
magnetoencephalography (MEG), 122, 182, 183, 184–185, 194
Mahalanobis distance, scatter, 46
major depression, hippocampal atrophy, 64
maladaptive behavior, 494
malingering see intra-individual variability
mapping therapy, phrase/sentence level treatment, 439
masked outcome trials, methodological quality
evaluation, 112
maturation
adult neurogenesis, 348
rehabilitation research, 83
mean arterial blood pressure change, exercise, 259
mean effect size (MES), CIMT efficacy, 406
“mechanism targeted” techniques, rehabilitation
research, 80
medial prefrontal cortex (mPFC) lesions
animal models of plasticity, 14
plasticity, 14
medial temporal areas, aging-related changes, 153, 155
median–split partition, inter-individual variability, 42
median temporal lobe, focal brain lesion localization, 134
mediators, psychosocial factors, 234
medical diseases/disorders
apathy see apathy
depression, 207
MEG see magnetoencephalography (MEG)
Melodic Intonation Therapy (MIT), 440, 441
memantine, 341–342
memory, 299, 313
adrenalectomy, 65
Alzheimer’s disease see Alzheimer’s disease assessment, 97
corticosteroid effects, 65–66
corticosterone, 65, 66
Cushing’s disease, 66
in elderly see memory, aging effects
evolutionary aspects, 534–535
estrogen, 67
insulin signaling see insulin, signaling measures, 93
neural substrate, 298
outcome measures, 114
post-injury rehabilitation see memory rehabilitation,
post-injury problems, 399
rehabilitation see memory rehabilitation
memory, aging effects, 149, 541–543
memory aids, 524–526
Memory Compensation Questionnaire, 26
Memory Failures Questionnaire, 97
memory performance prediction, anosognosia therapy
outcome, 220, 221
memory rehabilitation
language training, Alzheimer’s disease, 256
paging systems, 531
pharmacologic therapy, 312–313
memory rehabilitation, elderly, 541–561
memory rehabilitation, post-injury, 522–540
meningiomas, 469
mental fatigue, dispersion, 50
mental imagery training, neglect syndrome
rehabilitation, 452
mental processing speed, MRI subcortical
hyperintensities, 132
mental slowness, attention rehabilitation see attention,
rehabilitation post-TBI
mental state examinations, depression, 209
meta-analysis, longitudinal studies, 428
metabolic syndrome, cognitive impairment, 276
metacognition, 464, 467
anatomic principles, 465
developmental studies, TBI in children, 498
rehabilitation see below
Metacognition Index, 495
metacognitive function rehabilitation, 470,
475–476, 478
methodological quality evaluation, 108–109
blinding, 112–113
controls, 113–114
eligibility criteria, 111–112
GRADE working group, 109
indicators, 108, 110
levels of evidence, 110
outcome measures, 114–115
randomization, 111
statistical analyses, 110, 115
treatment descriptions, 113–114
methylphenidate, 301
attention, 312, 510, 512
executive functions, 313
memory, 313
TBI, 324
in children, 498
working memory, 313
methylprednisolone, 305
microangiopathy, cerebral see cerebral microangiopathy
microbleeds, MRI subcortical hyperintensities, 131
microglia, ischemic vascular disease, 362
microinfarcts, ischemic vascular disease, 362
middle cerebral artery, stroke, 468, 469
Mild Cognitive Impairment (MCI)
age-related memory rehabilitation, 545
Alzheimer’s disease see Alzheimer’s disease
exercise effects, 250
pharmacological therapy see Alzheimer’s disease, pharmacological therapy
physical activity vs., 266
mineralocorticoid(s), 63, 64
mineralocorticoid receptor (MR), 64
Mini-Mental State Examination (MMSE), 251
Alzheimer’s disease, 262
exercise training, 252
cerebral microangiopathy, 370
clinical trials, vascular dementia, 343
dementia, 338, 339, 340
exercise intervention studies, 257
exercise/physical activity, 252, 257, 425
minimization, variability, 41
minimum-norm solutions, neuroelectric recordings, 185
Minnesota Leisure Time Questionnaire, 425
mismatch negativity (MMN) see auditory learning
mixed vascular-Alzheimer’s disease
dementia, 361
MMSE see Mini-Mental State Examination (MMSE)
mnemonics, 399
age-related memory rehabilitation, 545, 546
post-injury memory rehabilitation see memory rehabilitation, post-injury
semantic memory rehabilitation, 533
mobile phones, memory impairment rehabilitation see memory rehabilitation, post-injury
models, compensation, 28
moderators, psychosocial factors, 234, 239
Modified Mini-Mental Status Examination, 338
“moment-to-moment” variability, 43
monoamine oxidase B inhibitors, 308
mood, 203, 205–217
activity assessment, 94
frontotemporal lobar degenerations, 336
outcome measures, 95–96
mood stabilizers, bipolar affective disorder, 210, 211
mormetric studies
ADHD, 489
TBI in children, 489
Morris water maze (MWM)
behavioral animal studies, 418
estrogen, 67
neurogenesis, 421
Moss Attention Rating Scale (MARS), 98
motivation, 203, 205–217
motoractivity log (MAL), CIMT efficacy, 406, 411
Motor Assessment Scale, 93
motor competence, neurological recovery, 169
motor cortex
exercise/physical activity, 420
neurological recovery, 166, 167
motor dexterity, MRI subcortical hyperintensities, 132
motor neglect, neglect syndrome, 449
motor reorganization, neurological recovery, 166
motor symptoms, Parkinsonism, 336
motor system upregulation, neurological recovery, 167
MRI see magnetic resonance imaging (MRI)
MS Impact Scale, 100
multifactorial memory training programs, 546
multilevel integration see cognitive neurorehabilitation
multiple cognitive problems, memory, 536
multiple group studies, 42
multiple level domains, 87
multiple sclerosis
activity assessment, 95
assessment
Assessment of Motor and Process Skills, 95
Functional Assessment of MS, 95
depression see depression
magnetization transfer imaging, 133
MRI, 130, 144, 207
pseudodementia, 209
myoinositol, magnetic resonance spectroscopy, 133
naloxone, 310
name, face pairs, elderly memory rehabilitation, 552
names
memory impairment rehabilitation, 527
objects, neglect syndrome, 450
word level treatments, 437
National Cancer Institute, rehabilitation research phase
models, 82
N-back task, working memory in children,
post-TBI, 490
neck/back pain therapy, methodological quality
evaluation, 109
neck muscle vibration (NMV), neglect syndrome
rehabilitation, 455, 571
necrosis
intracellular calcium ions, 304
secondary neurological diseases/disorders, 303
neglect-alerting device, 454
neglect syndrome, 571
anosognosia, 449
bedside tests for, 450
cognitive defects, 450
extrapersonal neglect, 449
lesion heterogeneity, 449, 460
motor neglect, 449
nonspatial mechanisms, 451
peripersonal neglect, 449
personal neglect, 449
rehabilitation see below
spatial mechanisms, 450
unilateral brain injury, 449
neglect syndrome rehabilitation, 449–463
neonatal injury models, neural stem cell therapy, 386
nerve growth factor (NGF), 307
enriched housing effects, 382
nerve growth factor family, 306
see also specific types
neural activity measurement see auditory learning
neural axis activation, executive functioning, 489
neural compensation, compensation, 26
neural correlates
memory in elderly see memory, aging effects
spatial neglect recovery see spatial neglect recovery
neural networks, TBI, 322
neural pathway identification, psychosocial factors, 244
neural recruitment drawbacks, compensation, 31
neural shock, CIMT, 402
neural stem cells (NSCs), 378–379
neural stem cell therapy, 296, 307, 376–393
neural structure effects, corticosteroids, 64–65
neural substrate, 298–302
neuritic plaques (NPs), Alzheimer’s disease, 334
Neurobehavioral Functioning Inventory, 100
Neurobehavioral Rating Scale, 100
neurochemistry, 298–302
see also specific components
neuroelectric recordings, 182–199
neuroelectric source imaging, CIMT, 404
neurofibrillary tangles, Alzheimer’s disease, 334
neurogenesis, 296, 348–359
adrenalectomy, 65
in adult, 348–351, 378, 379
aging vs., 381
androgens, 68
cognition, 351, 381
compensation, 30
corticosteroids, 65
dentate gyrus, 65
dietary restriction, 70
environmental manipulations, 377, 379–382, 387
exercise/physical activity see exercise/
physical activity
fibroblast growth factor, 382
gonadal steroids, 66
human applicability, 356–358
IGF-1, 69
markers, 349
pharmacological therapy, 306
in regeneration, 352–353
stages, 350
stress, 65
therapeutic potential, 353–356
neurogenin-2 expression, 384
neuroimaging see imaging
neurokinin family, 306
see also specific types
neurological diseases/disorders
  activity vs., 327
  behavior spectrum classification, 311
  commonalities, 298
  measures, 93–94
  neuropathology, 298
  prevalence, 298
  secondary, 303
  therapy, classification, 310
  see also specific diseases/disorders
neurological recovery, 166–169
neuromagnetic recordings, 182–199
neuronal growth, high-fat diets, 277
neuronal networks, age-related plasticity, 13
neuronal signaling cascades, high-fat diets, 277
neuron replacement, neural stem cell therapy, 386
NeuroPage, paging systems, 531
neuropathic pain (allodynia), neural stem cell transplantation, 384
neuropathology
  insulin signaling see insulin, signaling
  TBI see traumatic brain injury (TBI)
neuroplasticity see plasticity
neuroprotectin D1, 279
neuroprotective molecules, 303, 304
  exercise/physical activity, 418
neuropsychiatric disorders, intra-individual variability, 49
Neuropsychiatric Inventory (NPI)
  clinical trials, 342
  frontotemporal lobar degenerations, 342
  mood assessment, 96
neuropsychological functioning studies, outcome measures, 114
Neuropsychological Test Battery, 338
neurorehabilitation research, 79–90
animal models of plasticity, 15
  evaluation, 106–118
  see also Rothi’s revision of the Robey model
  outcome measures, 79, 87–88
  phase models, 81–82
  randomization, 111
  see also clinical trials
neurotoxicity
  aspartate, 303
  glutamate, 303
neurotransmission, high-fat diets, 277
neurotransmitter(s), 295
  frontal subcortical circuits, 206
neurogenesis, 354
  TBI see traumatic brain injury (TBI)
  working memory, 299
  see also specific neurotransmitters; specific systems
neurotransmitter receptors, injury, 162
neurotrophic factors
  exercise/physical activity see exercise/physical activity
  neurogenesis, 382
  see also specific factors
neurotrophin(s)
  families, 306
  high-fat diets, 277
  insulin resistance, 277
  in pharmacologic therapy, 306–307
  see also specific types
neurotrophin 3 (NT3), 307
neurotrophin 4 (NT4), 307
“neurovascular coupling”, functional imaging, 164
new group construction, inter-individual variability, 42
new learning
  memory impairment rehabilitation see memory rehabilitation, post-injury
  mnemonics, 528
  semantic memory rehabilitation, 533
new skill substitution, compensation, 26
nicotine, plasticity in rehabilitation, 15
nicotinic acetylcholine receptors, Alzheimer’s disease, 335
nitric oxide, 261–262
NMDA receptor(s), excitatory amino acids, 303
NMDA-receptor antagonists
  excitatory amino acids, 304
  Parkinson’s disease, 341
noise cancellation, magnetoencephalography, 185
noncognitive skills, executive functioning, 487
non-design factors, methodological quality evaluation, 108
nonlinear transformation, imaging spatial normalization, 139
non-mnemonic methods see memory rehabilitation, elderly
non-neuronal growth factor family, 306
  see also specific types
non-stationarity, variability, 44–45
noradrenergic compounds, neglect syndrome, 460
noradrenergic function, 301–302
norepinephrine
  Parkinson’s disease, 337
  TBI, 322
  working memory, 299
  see also specific neurotransmitters; specific systems
normal aging, memory see memory, aging effects
normalization, neurological recovery see neurological recovery
notebooks, age-related memory rehabilitation, 554
Nottingham Extended Activities of Daily Living, 94
nucleus accumbens (NAcc), plasticity, 14
number sequences, age-related memory rehabilitation, 547
nutrition see diet/nutrition
obesity, Zucker rat model, 69
object encoding, aging-related changes, 155
object-integrated aids see memory rehabilitation, post-injury
object names, semantic memory rehabilitation, 533
observational studies
exercise/physical activity see exercise/physical activity
methodological quality evaluation, 109
occurrence rates, methodological quality evaluation, 109
omega-3 fatty acids, 278–279
opiate kappa receptor antagonists, 310
opiate peptide modulation, in injury/repair, 310
optimism see psychosocial factors
optokinetic stimulation, neglect syndrome rehabilitation, 456
orbitofrontal circuit see frontal subcortical circuits
orbitofrontal cortex (OFC), plasticity, 11
organic cognitive impairment see compensation
orienting system, attention, 299
orphan drugs, TBI, 330–331
outcome measures, 5, 91–92
activity, 91, 94–96
cognitive activity limitations see cognitive activity assessment
cognitive neurorehabilitation, 573
cognitive tests, 92
future work, 100–101
methodological quality evaluation see methodological quality evaluation
mood see mood
participation see participation
randomized controlled trials, 101
rehabilitation research see neurorehabilitation research selection of, 92–93
short-term, 115
social/occupational activities, 100
TBI in children, 498
validation, cognitive neurorehabilitation, 566
outcomes, 91–105
anosognosia therapy see anosognosia
comprehensive day treatment program studies, 240
single subject experimental methods, 328
outlying observations see variability
overactivation persistence, neurological recovery, 166
overcoming learned non-use, CIMT, 402–404
oxidative stress
insulin resistance, 276–277
type-2 diabetes mellitus, 276–277
PACE, verbal fluency, 440
Paced Auditory Serial Attention Task (PASAT)
attention rehabilitation, 515
effective/cognitive function rehabilitation, 472
paging systems see memory rehabilitation, post-injury
parahippocampus, aging-related changes, 152
cortex, 153
parenchymal lesions, ischemic vascular disease, 360
parent interviews, everyday activities in children, post-TBI, 495
Parkinsonism
Lewy bodies, 337
motor symptoms, 336
Parkinson’s disease
animal models, 384
effective exercise, 419
depression, 207, 208
functional imaging, 207, 208
6-hydroxydopamine administration, 419
idiopathic, 337
intra-individual variability, 48, 49
task factors, 47
neurotrophic factors
exercise/physical activity, 423
glial cell-lined derived see glial cell line-derived neurotrophic factors
pathology, 336–337
aging-related changes, 156
pharmacologic therapy
clinical trials, 342–343
NMDA-receptor antagonists, 341
stem cell therapy, 307
paroxetine, clinical trials, 342
partial cues, elderly memory rehabilitation, 552
participant characteristics, eligibility criteria, 112
participant numbers, methodological quality evaluation, 115
PASAT see Paced Auditory Serial Attention Task (PASAT)
passive avoidance tasks, behavioral animal studies, 419
passive listening, mismatch negativity, 190
passivity, Alzheimer’s disease, 264
Patient Competency Rating Scale (PCRS), 227–228
patient compliance, anosognosia
neurorehabilitation, 223
patient identification, 477
patient–patient comparisons, focal brain lesion localization, 136
peak capacity, cognitive function enhancement, 311
peptide hormone(s), 68–69
see also specific hormones
peptide hormone receptors, 68
perceptual learning, 186–191
definition, 183
see also auditory learning
perceptual sensitivity, TBI effects, 509
perceptual training, event-related potentials, 193
performance

cognitive function, 573
single subject experimental methods, 329
“performance oscillations”, variability, 39
“performance” tests, language assessment, 97
performing an action, age-related memory rehabilitation, 547
peripersonal neglect, 449
perisylvian cortex, aphasia recovery, 170
periventricular white matter hyperintensities (PVWMH), 128, 143
periventricular white matter lesions, 263
personal activities of daily living, 94
personal digital assistants, 530
personal factors, 232
personality effects
coping, 236
frontotemporal lobar degenerations, 336
personal neglect, 449
PET see positron emission tomography (PET)
pharmacologic therapy, 298–320
see also specific diseases/disorders; specific drugs/treatments
phase I clinical trials, 4
phase II clinical trials, 4
phase III clinical trials, 4
phase models, rehabilitation research see neurorehabilitation research
phenytoin, TBI, 323
phlebotomy, rehabilitation research, 80
phobias, compensation, 24
phoneme level, word level treatments, 437
phospholipases, intracellular calcium ions, 304
phrase level treatment see language production therapy
physical activity see exercise/physical activity
physical fitness
age-related memory rehabilitation, 549–550
see also exercise/physical activity
physiological dysfunctions, neurological recovery, 167, 175
physiological stimuli, neurogenesis, 354
psychotherapy, neurogenesis, 355, 356
PI3K/Akt signal transduction
docosahexaenoic acid, 279
polyphenols, 279
Pick bodies, 336
Pick’s disease, pathology, 336
pitch discrimination tests see neuroelectric recordings;
neuromagnetic recordings
planimetric tracing methods, structural neuroimaging, 124
planning see problem-solving/planning
plasticity, 3, 6–21
codeine and amphetamine regulated transcript, 68
cognition, 351
imaging, 182
insulin signaling, 275
lesion-behavior analysis, 141
neural stem cell therapy, 386
neurological recovery, 175
pharmacologic therapy, 306
rehabilitation research, 80
points of translation, rehabilitation research, 79
polyphenols see dietary antioxidants
population factors, intra-individual variability see intra-individual variability
population selectivity, eligibility criteria, 111
Porteus Maze test, 492
positron emission tomography (PET), 163
ADHD, 489
anosognosia, 221
anosognosia treatment, 226
aphasia treatment, 226
aphasia recovery, 169
CIMT, 404
compensation, 30, 31
depression, 207, 208
depression assessment, 210
Huntington’s disease, 208
lesion-behavior analysis, 140
Parkinson’s disease, 207
posterior cortex, executive functioning, 488
postmortem studies, "mild cognitive impairment", 335
post-stroke nonfluent aphasia, compensation, 32
post-traumatic amnesia (PTA)
anosognosia therapy outcome, 221
TBI, 322
post-traumatic stress disorder (PTSD)
hippocampal atrophy, 64
TBI in children, 489
postural control, prism adaptation, 456
practical aspects, single subject experimental methods, 328–330
practical clinical trials (PCTs), 113
practicality, outcome measures, 92
practical tasks, visual neglect assessment, 98
practice
age-related memory rehabilitation, 549
intra-individual variability, 47
outcome measures, 92
predicted task performance, deficit awareness, 475
predictors, psychosocial factors, 234
prefrontal cortex (PFC)
alpha-2-adrenergic receptors, 301
executive functions, 300
memory, aging effects, 543
subregions, executive functioning, 488
prenatal stress, plasticity, 14
primary apathy, 212
primary prevention
pharmacological therapy, 302–303, 314
stroke, 302
substance abuse, 303
TBI, 302
primary progressive aphasia (PPA), 336
primate studies
CIMT, 402, 403
neglect syndrome rehabilitation, 459
prior experience, plasticity, 14
prism adaptation see neglect syndrome rehabilitation
Problems in Everyday Living Questionnaire, 97
problem-solving/planning
behavioral/emotional function rehabilitation, 473
in children, 492
coping, 235
executive/cognitive function rehabilitation see executive dysfunction, rehabilitation
executive functions assessment, 99
procedural memory
age-related memory rehabilitation, 551–553
Alzheimer's disease, 543
process, definition, 91
professional development/training, cognitive neurorehabilitation, 573
Profile of Functional Impairment in Communication, 99
progesterone, 67
progressive disorders
intra-individual variability, 48
pharmacological therapy, 302
see also specific diseases/disorders
progressive supranuclear palsy (PSP), 336
prolactin, neural stem cell therapy, 382, 383
prompts, word level treatments, 437
prosopagnosia, semantic memory rehabilitation, 533
prospective aids, proximal memory aids, 525
prospective memory, aging effects, 542
protease activity modulators, 305–306
protective safety mitt, CIMT, 410
proton density (PD), MRI, 126
proximal memory aids see memory rehabilitation, post-injury
pseudobulbar affect, 211
pseudodementia see depression
psychiatric disorders, aging-related changes, 156
psychoactive drugs, plasticity, 10, 14
psychological tests, impairment measures, 93
psychomotor activation programme (PAP), 258
psychomotor stimulants, plasticity in rehabilitation, 15
psychopharmacology, ADHD, 499
psychosocial factors, 204, 232–241
psychosocial training, psychosocial factors, 243
psychostimulants, apathy, 213
psychotherapy
apathy, 213
attention rehabilitation see attention, rehabilitation post-TBI
depression, 210
memory impairment rehabilitation, 536
psychosocial factors, 243
PTA see post-traumatic amnesia (PTA)
PTSD see post-traumatic stress disorder (PTSD)
public policy effects, Rothi's revision of the Robey model, 86
pyramidal cells, plasticity, 17
quality of life measures, 91, 92
dementia intervention studies, 338
participation assessment, 100
quality of practice, aphasia therapy, 444
quantitative magnetic resonance imaging, cerebral microangiopathy, 369
quetiapine, bipolar affective disorder, 211
quinidine, pseudobulbar affect treatment, 211
Rancho Los Angeles Scale, 99
randomization
exercise/physical activity longitudinal studies, 427
methodological quality evaluation see methodological quality evaluation
randomized clinical trials (RCTs), 4, 81, 107
neglect-alerting device, 454
neglect syndrome rehabilitation, 451
outcome measures see outcome measures
requirements of, 82
tele-rehabilitation, 242
treatment efficacy, 82
visual scanning, 452
see also specific drugs
caphe nucleus, 336
Rating Scale of Attentional Behavior, 98
rating scales, MRI subcortical hyperintensities, 131
rat models/studies
exercise/physical activity, 420
stroke models, 378
RBMT see Rivermead Behavioral Memory Test (RBMT)
reaction time (RT)
energization functions, 466
executive cognitive functions, 466
variability, 39
reactive oxygen species (ROS), 305
recognition memory, age-related memory
rehabilitation, 546
recognition tasks
aging-related changes, 155
compensation, 30
recollection
age-related memory rehabilitation, 548–549
definition, 548
recruitment
randomized controlled trials, 101
rehabilitation research, 79
regional metabolic glucose metabolism, aphasia, 170
rehabilitation see neurorehabilitation
"rehabilitation probe" experiments, 471
rehearsal
aging-related changes, 151
techniques, 537
relational views, psychosocial factors, 233
relaxation therapy, 535
reliability, outcome measures, 92
remediation
compensation, 26
organic cognitive impairment, 29
reminiscence therapy, dementia, 257
remote memory cueing, 524
reorganized activity, aphasia, 170
repeated crossover design, 328
repetitive task-oriented training see constraint-induced movement therapy (CIMT)
repetitive transcranial magnetic stimulation (rTMS), 458
repinotan, 310
phase I clinical trials, 310
phase II clinical trials, 310
residential homes, distal memory aids, 525
Response Elaboration Training (RET), 440, 441
response time distributions, variability, 45
restorative care, community-based interventions, 241
retention effects, aphasia therapy, 443
reviews (of cognitive rehabilitation), 107–108
right hemisphere
hypodensity, computerised tomography, 137
recruitment, aphasia recovery see aphasia
stroke, anosognosia therapy outcome, 220
risperidone, bipolar affective disorder, 211
rivastigmine
attention, 312
clinical trials
Alzheimer’s disease, 340
dementia with Lewy bodies, 342
frontotemporal lobar degenerations, 342
Rivermead Behavioral Memory Test (RBMT)
cognitive activity assessment, 96, 97
language assessment, 97
Rivermead Head Injury Follow-Up Questionnaire, 95
Rivermead Motor Assessment, 93
Robey’s five-phase model, 82
rotational forces, TBI, 507
Rothi’s multistage model, 4
Rothi’s revision of the Robey model, 82, 85
running, neurogenesis, 356
SART see Sustain Attention and Response task (SART)
saturated fats, diet/nutrition, 280
scanning board, neglect syndrome rehabilitation, 454
<table>
<thead>
<tr>
<th>Topic</th>
<th>507-548</th>
</tr>
</thead>
<tbody>
<tr>
<td>scatter</td>
<td>41, 46</td>
</tr>
<tr>
<td>clinical implications</td>
<td>51</td>
</tr>
<tr>
<td>group variability</td>
<td>52</td>
</tr>
<tr>
<td>mechanism</td>
<td>50</td>
</tr>
<tr>
<td>schizophrenia</td>
<td></td>
</tr>
<tr>
<td>intra-individual variability</td>
<td>49</td>
</tr>
<tr>
<td>plasticity</td>
<td>17</td>
</tr>
<tr>
<td>school breakfast programs</td>
<td>281</td>
</tr>
<tr>
<td>schooling, age-related memory rehabilitation</td>
<td>549</td>
</tr>
<tr>
<td>secondary apathy</td>
<td>212</td>
</tr>
<tr>
<td>secondary emotional disturbances, TBI in children</td>
<td>489</td>
</tr>
<tr>
<td>sedatives, TBI</td>
<td>323</td>
</tr>
<tr>
<td>sedentary lifestyle, energy balance</td>
<td>70</td>
</tr>
<tr>
<td>selective attention</td>
<td></td>
</tr>
<tr>
<td>neglect syndrome</td>
<td>451</td>
</tr>
<tr>
<td>TBI effects</td>
<td>509</td>
</tr>
<tr>
<td>selective attention rehabilitation</td>
<td></td>
</tr>
<tr>
<td>rehabilitation post-TBI</td>
<td></td>
</tr>
<tr>
<td>selective serotonin reuptake inhibitors (SSRIs)</td>
<td></td>
</tr>
<tr>
<td>apathy</td>
<td>213</td>
</tr>
<tr>
<td>clinical trials</td>
<td>342</td>
</tr>
<tr>
<td>depression</td>
<td>207, 210</td>
</tr>
<tr>
<td>pseudobulbar affect treatment</td>
<td>211</td>
</tr>
<tr>
<td>self-awareness</td>
<td></td>
</tr>
<tr>
<td>impaired see anosognosia</td>
<td></td>
</tr>
<tr>
<td>self-efficacy</td>
<td>237</td>
</tr>
<tr>
<td>self-efficacy see psychosocial factors</td>
<td></td>
</tr>
<tr>
<td>self-generated strategies see memory rehabilitation, elderly</td>
<td></td>
</tr>
<tr>
<td>self-harm, depression</td>
<td>208</td>
</tr>
<tr>
<td>self-instructional techniques, Brief Mindfulness Training</td>
<td>511</td>
</tr>
<tr>
<td>self-limiting beliefs, psychosocial factors</td>
<td>233</td>
</tr>
<tr>
<td>self-monitoring</td>
<td></td>
</tr>
<tr>
<td>attention rehabilitation</td>
<td>508–510</td>
</tr>
<tr>
<td>verbal fluency</td>
<td>440</td>
</tr>
<tr>
<td>self-monitoring training (SMT), error awareness/self-monitoring</td>
<td>476</td>
</tr>
<tr>
<td>self-pointing measure</td>
<td>490</td>
</tr>
<tr>
<td>self-referential processing, age-related memory rehabilitation</td>
<td></td>
</tr>
<tr>
<td>semantic memory</td>
<td></td>
</tr>
<tr>
<td>aging effects</td>
<td>150, 542, 543, 544</td>
</tr>
<tr>
<td>Alzheimer’s disease</td>
<td>543</td>
</tr>
<tr>
<td>anoma</td>
<td>533</td>
</tr>
<tr>
<td>compensation</td>
<td>31</td>
</tr>
<tr>
<td>definition</td>
<td>532</td>
</tr>
<tr>
<td>rehabilitation</td>
<td>532–534</td>
</tr>
<tr>
<td>semantic networks, word level treatments</td>
<td>438</td>
</tr>
<tr>
<td>semantic processing, aging-related changes</td>
<td>151</td>
</tr>
<tr>
<td>semi-automated image segmentation</td>
<td>429</td>
</tr>
<tr>
<td>senile plaques (SPs), Alzheimer’s disease</td>
<td>334</td>
</tr>
<tr>
<td>sensitivity, outcome measures</td>
<td>92</td>
</tr>
<tr>
<td>sensory impairment, impairment measures</td>
<td>93</td>
</tr>
<tr>
<td>sensory motor representation topography</td>
<td></td>
</tr>
<tr>
<td>see neurological recovery</td>
<td></td>
</tr>
<tr>
<td>sensory selective attentional system</td>
<td>508</td>
</tr>
<tr>
<td>sentence level training see language production therapy</td>
<td></td>
</tr>
<tr>
<td>serial correlation, variability</td>
<td>44</td>
</tr>
<tr>
<td>serotonergic system, executive functions</td>
<td>300</td>
</tr>
<tr>
<td>serotonin</td>
<td></td>
</tr>
<tr>
<td>frontal subcortical circuits</td>
<td>206</td>
</tr>
<tr>
<td>Parkinson’s disease</td>
<td>337</td>
</tr>
<tr>
<td>TBI, 322</td>
<td></td>
</tr>
<tr>
<td>serotonin 1a (SHT1a) receptor</td>
<td>309</td>
</tr>
<tr>
<td>serotonin 1a (SHT1a) receptor agonists</td>
<td>310</td>
</tr>
<tr>
<td>serotonergic system dysfunction</td>
<td>262</td>
</tr>
<tr>
<td>sertraline</td>
<td>475</td>
</tr>
<tr>
<td>Severe Impairment Battery (SIB)</td>
<td>338</td>
</tr>
<tr>
<td>sexual-dimorphic responses, plasticity</td>
<td>14</td>
</tr>
<tr>
<td>Shapes Task</td>
<td>98</td>
</tr>
<tr>
<td>shifting</td>
<td></td>
</tr>
<tr>
<td>in children, 491–492</td>
<td></td>
</tr>
<tr>
<td>definition</td>
<td>491</td>
</tr>
<tr>
<td>Short Form 5, 100</td>
<td></td>
</tr>
<tr>
<td>short-term memory</td>
<td></td>
</tr>
<tr>
<td>aging effects</td>
<td>542</td>
</tr>
<tr>
<td>Alzheimer’s disease exercise training</td>
<td>252</td>
</tr>
<tr>
<td>Sickness Impact Profile</td>
<td>95</td>
</tr>
<tr>
<td>signal-to-noise ratio, neuroelectric recordings</td>
<td>186</td>
</tr>
<tr>
<td>signal transduction effects, polyphenols</td>
<td>279</td>
</tr>
<tr>
<td>signs, distal memory aids</td>
<td>525</td>
</tr>
<tr>
<td>simple discrimination tasks, visual evoked responses</td>
<td>191</td>
</tr>
<tr>
<td>Simulated Real Life Tasks (SRLTs)</td>
<td>473</td>
</tr>
<tr>
<td>single-case design, outcome measures</td>
<td>92</td>
</tr>
<tr>
<td>single cell recordings</td>
<td>182</td>
</tr>
<tr>
<td>single level therapies, aphasia therapy</td>
<td>444</td>
</tr>
</tbody>
</table>
single-photon excitation computerized tomography (SPECT), vascular dementia, 263
single subject experimental methods, 326
blind multiple cross-over trials, 329
data storage/analysis, 329
ethics, 328
Institutional Review Boards, 328
outcomes, 328
performance data, 329
practical aspects, 328–330
TBI therapy, 326–328
situational factors see intra-individual variability
SIVD see subcortical ischemic vascular dementia (SIVD)
skewed distributions, 45
skills, age-related memory rehabilitation, 553
SMA, aphasia recovery, 171
social control variables, 234
social engagement, apathy, 212
social experiences, plasticity, 10
social history, depression, 208
social interventions, apathy, 213
social isolation, memory impairment rehabilitation, 534
social skills training, 243
social support, 70
society effects, outcome measures, 87
somatosensory deficits, 456
somatosensory evoked responses, 192
somatosensory processing, event-related potentials, 194
songbird high vocal center (HVC), androgens, 68
sonic hedgehog, neurogenesis, 306
source analysis, neuroelectric recordings see neuroelectric recordings
source memory
aging-related changes, 149
compensation, 30
errorless learning, 529
spaced retrieval (SR)
age-related memory rehabilitation, 551–552
Alzheimer’s disease, 551
explicit memory rehabilitation, 552
word level treatments, 438
space remapping training, 458
space-representation alteration see neglect syndrome rehabilitation
spatial gradient of attention, 451
spatial learning, glucocorticoid receptor, 66
spatial mechanisms, neglect syndrome see neglect syndrome
spatial memory tasks, neurogenesis, 381
spatial neglect, 398
behavioral dissociations, 172
prevalence, 172
spatial neglect recovery
bi-hemispheric acute suppression, 172–173
blood oxygen level dependent signal, 174
chronic reactivation, 172–173
functional connectivity breakdown, 174
interhemispheric imbalance, 173–174
over-activation, 173
“push-pull” imbalance, 173
sensory signals, 173
sub-acute stage, 172
spatial normalization
imaging see imaging
lesion-behavior analysis, 140
spatial working memory, 300
in children, post-TBI, 490
neglect syndrome, 451
specific skill training, selective attention rehabilitation, 512
spine density, plasticity, 11
stability, coping, 236
standard deviation
scatter, 46
variability, 44
Statistical Parametric Mapping (SPM), 138
statistics
inter-individual variability, 42
methodological quality evaluation see methodological quality evaluation
overlap methods, focal brain lesions, 137
stem cell therapy see neural stem cell therapy
steroid therapy, Cushing’s disease, 70
stimulus dependency, plasticity, 16
stop signal reaction time task, TBI vs. ADHD, 496
stress
chronic
amygdala, 65
CA3, 64
corticosteroids, 64
corticosterone, 64
cocaine and amphetamine regulated transcript, 63
hormones, 63
insulin, 63
leptin, 63
neurogenesis, 65
Index

striatum
adult neurogenesis, 350
exercise/physical activity, 420
frontal subcortical circuits, 206
plasticity, 10
stroke, 468
aging-related changes vs., 154
animal models, 378
anosognosia therapy outcome, 221
classification, 376
Barthel Index, 94
deficits, 377
dementia see vascular dementia (VaD)
depression, 207
dorsolateral stroke syndrome, 468
epidemiology, 125, 401
etiology
anterior cerebral artery aneurysms, 468, 469
anterior communicating artery, 468, 470
frontal lobe disorder, 468
middle cerebral artery, 468, 469
imaging, 122
see also specific methods
incidence, 371
neurologic recovery, 162, 166, 371
plasticity, 12
primary prevention, 302
reviews, 107
subcortical, 168
therapy
amphetamines, 308
CIMT, 377
combinations, 377
community-based interventions, 241
diazepam, 309
effectiveness evidence, 107
event relevance, 17
methodological quality evaluation, 109
neural stem cell therapy see neural stem cell therapy
physiotherapy, 356
psychosocial factors, 233
rehabilitation therapy, 377
tissue plasminogen activator, 377, 387
see also cerebral small vessel disease; cerebrovascular disease
Stroke Aphasic Depression Questionnaire, 96
“stroke-induced neurogenesis”, 362
Stroop Color Word and Trail Making, 98
structural equation modeling analysis, exercise/physical activity, 424
structural imaging, 124–148
memory impairment rehabilitation, 532
structural magnetic resonance imaging, 121
exercise/physical activity, 427
structured teaching, memory impairment rehabilitation, 522
study comparisons, intra-individual variability, 43
study time, age-related memory rehabilitation, 549
subcortical ischemic vascular dementia (SIVD), 260
exercise, negative findings, 259
gait disorders, 266
subcortical strokes, neurological recovery, 168
subcortical structure, executive functioning, 488
subjective bias, research evaluation, 106
Subjective Memory Assessment Questionnaire, 97
“subsequent memory effect”, aging-related changes, 153
substance abuse, 303
substantia nigra, frontal subcortical circuits, 206
substitution, organic cognitive impairment, 29
subventricular zone (SVZ), neurogenesis, 378, 379
suicidal thoughts, depression, 208
superconducting quantum interference devices (SQUID), 185
supplementary motor area, aphasia recovery, 171
surrogate markers, plasticity, 7
Sustain Attention and Response task (SART) attention, 508
TBI effects, 509, 510
sustained attention, neglect syndrome, 451, 453
Symbol Digit Modalities test, 339
synaptic organization, pharmacologic therapy, 306–307
systematic reviews (of cognitive rehabilitation), 108
tacrine, clinical trials, 339
tactile stimulation, plasticity, 15
Talairach stereotactic coordinate system, 140
TAP program, 440
targeted remediation programs, 476
task banks, CIMT, 408
task-dependent changes, plasticity, 11
task factors see intra-individual variability
task practice, CIMT, 407, 408
task selection, CIMT, 408
taste aversion conditioning, plasticity, 16
telephone therapy, auditory comprehension treatments, 442
tele-rehabilitation see psychosocial factors
temporal frontal regions, aging-related changes, 155
temporal information
EEG, 183
magnetoencephalography, 183
Test of Everyday Attention (TEA) attention assessment, 98
cognitive activity assessment, 97
testosterone, 68
neurogenesis, 352
test-retest reliability, definition, 92
thalamus, frontal subcortical circuits, 206
three-dimensional magnetic resonance imaging see magnetic resonance imaging (MRI)
“three vectors of consciousness”, anosognosia treatment, 226
thrombosis, nitric oxide, 261
tianeptine, 65
time-dependency, plasticity see plasticity
time for performance, cognitive function enhancement, 311
time of day, age-related memory rehabilitation, 550
Time Pressure Management (TPM), 513
time scales, intra-individual variability, 43
time-series, neuroelectric recordings, 186, 187
time since injury, frontal lobe function rehabilitation, 478
Tirilazad, 305
tissue plasminogen activator (tPA), stroke, 377, 387
Token Test, 441
tolerability, randomized clinical trials, 81
tools, cognitive neurorehabilitation, 567
topographical changes
event-related fields, 193
event-related potentials, 193
neuroelectric recordings, 183
neuromagnetic recordings, 183
Tower of London task, 492
Trail Making Test attention, 508, 512
executive/cognitive function rehabilitation, 472
trainer-trainee interaction patterns, psychosocial factors, 243
training
auditory comprehension treatments, 441
mismatch negativity, 190
neurogenesis, 353
retrieval processes see memory rehabilitation, elderly
somatosensory evoked responses, 192
visual evoked responses, 191
transcranial magnetic stimulation (TMS), 167
CIMT, 404, 405
“transfer packages”, CIMT, 410
translational linkages, cognitive neurorehabilitation, 567
translational research
definition, 80
rehabilitation research, 80
translation stage, Rothi’s multistage model, 4
transplantation, neural stem cells see neural stem cell therapy
trauma compensation, 25
neurogenesis, 352
plasticity in brain injury, 12
traumatic brain injury (TBI), 469
case study, variability, 52
children see below
classification, 303
cognitive sequelae, 322, 507
compensation, 30
DA, 307
eeptephrine, 307
incidence, 468, 507
intra-individual variability see intra-individual variability
neuropathology, 321
neurotransmitters, 321, 322
pathogenesis
focal parenchymal injury, 469
frontal lobe disorder, 468
Patient Competency Rating Scale, 227
pharmacological therapy, 295, 321–333
primary prevention, 302
rehabilitation therapy
case study, 54
effectiveness evidence, 107
intra-individual variability, 53
psychosocial factors, 233
treatment effectiveness evidence, 107
reviews (of cognitive rehabilitation), 107
secondary effects, 507
studies
eligibility criteria, 112
error awareness/self-monitoring, 476
randomisation, 111
self-efficacy, 237
behavioral therapy, 399
community-based interventions, 241
memory see memory rehabilitation, post-injury
pharmacological therapy see above
rehabilitation therapy see above
stem cell therapy, 307
tele-rehabilitation, 242
Index

traumatic brain injury (TBI), children
ADHD vs. see attention deficit hyperactivity disorder (ADHD)
behavioral self-regulation, 494
decision making/motivation, 493
everyday activities, 494–495
executive functioning, 487, 488
inhibition, 491
neural substrate, 489
neurocircuitry, 497
planning, 492
recovery/treatment, 497–499
traumatic spinal cord injury (TSCI), anosognosia, 222
trazodone, clinical trials, 342
treatment allocation concealment, randomization, 111
treatment descriptions, methodological quality evaluation see methodological quality evaluation
treatment efficacy, randomized clinical trials, 82
treatment outcome evaluation, outcome measures, 87
treatment periods, blind multiple cross-over trials, 329
tricyclic antidepressants, depression, 210
tumor necrosis factor-alpha, type-2 diabetes mellitus, 276
tumors, 468–469	
two-dimensional magnetic resonance imaging, 135
type 1 allostatic load, allostatics, 62
type 2 allostatic load, allostatics, 62
type-2 diabetes mellitus
acute diet, 281
chronic diet, 273
inflammation, 276–277
insulin signaling, 273, 274
oxidative stress, 276–277
tumor necrosis factor-alpha, 276
unilateral brain injury, neglect syndrome, 449
unilateral spatial neglect
anosognosia comorbidity, 221
Rothi’s revision of the Robey model, 85
TBI effects, 508
use-dependent cortical reorganization see constraint-induced movement therapy (CIMT)

validation, psychosocial factors, 234
validity, outcome measures, 92, 100
valproate
bipolar affective disorder, 211
TBI, 324

vanishing cues, age-related memory
rehabilitation, 552
variability, 39–61
variance, 46
vascular cognitive impairment (VCI), 361
vascular cognitive impairment no dementia (vCIND), physical activity vs., 266
vascular dementia (VaD)
cerebral hypoperfusion, 263
definition, 251
executive dysfunction, 250, 264
exercise intervention studies, 256
gait disorders, 265, 266
homeostyene, 262
incidence, 337
intra-individual variability, 48
nitric oxide metabolism, 262
pathology, 337
pharmacological therapy, 343
vascular disease, 260–261
vascular disease, 250
Alzheimer’s disease see Alzheimer’s disease
basal forebrain, 260
cerebral hypoperfusion, 260–261
effects of, 266
exercise, 251, 259–265
frontotemporal dementia, 261
homeostyene, 261
physical activity decrease, 266
vascular dementia see vascular dementia (VaD)
see also specific diseases/disorders
vascular endothelial growth factor (VEGF)
exercise/physical activity, 420
neurogenesis, 422
neural stem cell therapy, 382, 383
neurogenesis, 379, 422
vascular injury, prevention of, 125
vasculitis, cerebral amyloid angiopathy, 365
vegetative state, TBI, 321
ventral hippocampal lesions, animal models of plasticity, 17
ventral prefrontal cortex (VPFC), 465, 466
ventral striatum, 488
ventrolateral prefrontal cortex, 488
ventromedial frontal cortex, 493
verbal apraxia, 136
verbal fluency, 439
card games, 441
definition, 440
discourse level training, 440
verbal fluency (cont.)
  functional conversation skills, 440
lesion-behavior analysis, 141
Melodic Intonational Therapy, 440, 441
PACE, 440
Response Elaboration Training, 440, 441
self-monitoring treatment, 440
TAP program, 440
see also entries under language
verbal memory, insulin signaling, 274
verbal reinstatement strategy, 476
verb retrieval treatment, 439
video feedback, neglect syndrome rehabilitation, 452
viral vectors, neurogenesis, 354
Virchow–Robin spaces, MRI, 127, 143
virtual reality, memory impairment rehabilitation, 531–532
Visual Analog Mood Scales, 96
visual area, 7
visual evoked responses, 191–192
visual imagery
  age-related memory rehabilitation see memory rehabilitation, elderly
  memory impairment rehabilitation, 527
mnemonics, 528
visual neglect assessment, 97–98
visual processing, Roth’s revision of the Robey model, 85
visual scanning, neglect syndrome rehabilitation, 452
visual stimuli processing, event-related potentials, 194
visual system, translational research, 84
visuomotor feedback, neglect syndrome rehabilitation, 452
visuoverbal measures, prism adaptation, 456
vitamin C, 283
vitamin E, 283
clinical trials, 340
volumetric MRI, TBI, 497
voluntary exercise
  behavioral animal studies, 419
  neurogenesis, 421
voluntary running behavior tests, 356
Voxel-based Lesion Symptom mapping, 140, 141
WAIS-III
  Patient Competency Rating Scale, 227
scatter, 50
WAIS-R, scatter, 50
walking/talking, Alzheimer’s disease therapy, 252, 256
war-related injuries, aphasia, 436
Weschler intelligence scales, scatter, 46
wheel running, behavioral animal studies, 418
white boards, proximal memory aids, 524
white matter
  cerebral hypoperfusion see cerebral hypoperfusion
  memory, aging effects, 543, 544
Wisconsin Card Sorting Test (WCST)
  ADHD, 491
  attention rehabilitation, 512
  in children, post TBI, 491
Wolf Motor Function Test (WMFT), 406
Women’s Health Initiative (WHI), 67
word level treatments see language production therapy
workbook interventions, psychosocial factors, 243
working alliances, post-TBI anosognosia therapy studies, 224
working memory, 299
A1A agonist effects, 301
aging effects, 150, 151, 542
catecholaminergic system, 299
children, 490
cholinergic system, 299
definition, 490
neurotransmitters, 299
pharmacologic therapy, 313
rehabilitation, 472
World Health Organization (WHO), rehabilitation research
  phase models, 81
Zucker rat model, obesity, 69